TY  - JOUR
AU  - Vaillant, Jan
AU  - Pal, Sangita
AU  - Müller, Jan
AU  - Wittmann, Andrea
AU  - Boakye-Yiadom, Akosua
AU  - Sievers, Philipp
AU  - Zimmer, Paula
AU  - Schoof, Melanie
AU  - Schelb, Franziska
AU  - Hofmann, Nina
AU  - Keck, Michaela-Kristina
AU  - Fabian, Tessa
AU  - Schüller, Ulrich
AU  - Zuckermann, Marc
AU  - Beroukhim, Rameen
AU  - Bandopadhayay, Pratiti
AU  - Jones, David T W
AU  - Kutscher, Lena
TI  - A Cre-mediated copy number variant compromises the reliability of a LoxP-STOP-LoxP-PLAG1 driven brain tumor model.
JO  - Neuro-oncology advances
VL  - 8
IS  - 1
SN  - 2632-2498
CY  - Oxford
PB  - Oxford University Press
M1  - DKFZ-2026-00456
SP  - vdaf251
PY  - 2026
N1  - #EA:B430#LA:B430# / #NCTZFB26# / #DKTKZFB26#
AB  - The developmental context in which genetic alterations occur is crucial to understand disease progression. In pediatric cancer, modeling tumor formation in the right cell type is necessary to faithfully recapitulate the unique nature of pediatric tumors. The Cre-LoxP system is a powerful tool to modulate gene expression in specific cell types at discrete developmental time windows.We used Cre-LoxP mouse models to study the role of the oncofetal transcription factor PLAG1 in pediatric brain tumor formation. We characterized our model using histology, DNA methylation based copy number variant (CNV) analysis on fresh frozen and FFPE derived samples, RNA sequencing, whole genome sequencing and whole genome CRISPR Cas9 screening.We generated a new model for PLAG1 overexpressing brain tumors, but discovered an unexpected CNV at the Nras locus by DNA methylation analysis. We confirmed the CNV via whole genome sequencing and found that it was likely mediated by Cre-recombination at the transgene insertion site. Both the tumor transcriptome and genetic dependencies are substantially shaped by this CNV.Our work demonstrates the necessity of copy-number analysis when working with transgenic Cre-LoxP mouse models. Assessing CNVs should become a standard evaluation procedure when reporting new tumor models, preventing misleading conclusions that could dramatically impact the reliability of preclinical studies.
KW  - CNV (Other)
KW  - PLAG1 (Other)
KW  - animal models (Other)
KW  - pediatric brain tumor (Other)
KW  - preclinical model (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41756758
C2  - pmc:PMC12932942
DO  - DOI:10.1093/noajnl/vdaf251
UR  - https://inrepo02.dkfz.de/record/310128
ER  -